Virtu Financial LLC 89bio, Inc. Transaction History

Virtu Financial LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 27, 2023	SELL	$14.15 - $22.03 $658,611 - $1.03 Million	-46,545 Reduced 82.21%	10,073 $191,000
Q1 2023 May 01, 2023	BUY	$10.48 - $16.94 $593,356 - $959,108	56,618 New	56,618 $862,000
Q3 2022 Nov 07, 2022	BUY	$3.02 - $7.0 $38,236 - $88,627	12,661 Added 62.61%	32,883 $190,000
Q2 2022 Aug 09, 2022	BUY	$2.09 - $4.02 $42,263 - $81,292	20,222 New	20,222 $65,000

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $387M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.